secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-09-08T12:01:57+00:00
Accession:  0001636282-26-000113
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre SPY003 Phase 2 UC: 10-point RHI reduction (p<0.0001), 20% remission, 30% endoscopic improvement
--------------------------------------------------------------------------------

- SPY003 met primary endpoint: 10.0-point reduction in RHI from baseline at Week 12 (p<0.0001) in 44 patients with moderate-to-severe UC.
- Secondary endpoints: 20% clinical remission by modified Mayo Score, 30% endoscopic improvement, -3.5 change in mMS.
- Safety: 19 TEAEs (43%), 3 SAEs deemed not drug-related, no drug-related SAEs or deaths; consistent with IL-23 class.
- Completes proof-of-concept for all three IBD components (SPY001, SPY002, SPY003); Part B combination trial enrolling, topline data expected 2027.
- Additional readouts: SKYWAY (SPY072) 4Q 2026; SKYLIGHT (HS) late 2027/early 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/0001636282-26-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer